ascending dose study

ascending dose study

A component of a phase-I clinical trial in which increasing doses of a drug are administered until the maximum tolerated dose is reached.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
The Phase 1 trial is a randomized, double-blind, placebo-controlled single ascending dose study of orally administered RE-024 in healthy volunteer subjects.
Biotechnology company Ascendis Pharma A/S (NasdaqGS:ASND) revealed on Tuesday that its Phase 1 single ascending dose study of TransCon Treprostinil produced dose-dependent increases in plasma treprostinil levels in-line with expectations.
The DDI study follows the completion of the first stage of the program, announced on September 18, 2018, where CRV431 met the primary endpoints of safety and tolerability in a single ascending dose study of healthy volunteers.
The product is a first-in-class, orally available activator of pyruvate kinase-R enzymes and the medicine met its primary endpoints in two Phase I healthy volunteer trials, including a single ascending dose study and multiple ascending dose study.
The single ascending dose study is expected to complete in the first half of 2019.
The Phase 1 study, designed to enroll up to 52 healthy volunteers, is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study intended to evaluate the safety and tolerability of PL-8177 administered via subcutaneous injection.
This study is the second phase I study conducted with CM-101, the first study was a single ascending dose study using the IV formulation.
In the first stage of CRV431's streamlined clinical program, CRV431 met the primary endpoints of safety and tolerability in a single ascending dose study of healthy volunteers.
It is an oral small molecule with well-established preclinical anti-fibrotic activity that has been earlier studied in healthy volunteers as part of a Phase one, single ascending dose study.
LYT-100, an oral small molecule with well-established preclinical anti-fibrotic activity, has been previously studied in healthy volunteers as part of a first phase, single ascending dose study.
Acesion added that the Phase 1 study was a randomised, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in 47 healthy subjects, conducted at the Centre for Human Drug Research (CHDR) in the Netherlands.